Tam D A, Morton L D, Stroncek D F, Leshner R T
Division of Child Neurology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
J Neuroimmunol. 1996 Feb;64(2):175-8. doi: 10.1016/0165-5728(95)00167-0.
A child with Guillain-Barre syndrome treated with intravenous immune globulin (IVIG) developed neutropenia (absolute neutrophil count = 390), which resolved 3 days after completion of the therapy. Potential mechanisms for the development of neutropenia during the use of IVIG therapy are discussed. In this case, testing of the IVIG used revealed the presence of a high concentration of anti-neutrophil antibodies compared to other samples. It is recommended that white blood cell and neutrophil counts be monitored daily during the use of such therapy.
